Cordis, Wyeth Urge Fed. Circ. To Revive Stent Patents

Law360, Washington (April 5, 2013, 5:13 PM EDT) -- A Federal Circuit panel on Friday mulled whether to reinstate two Cordis Corp. and Wyeth Pharmaceuticals Inc. drug-eluting stent patents nixed in an infringement battle with Abbott Laboratories and others, with judges suggesting that the patents may be too vague to justify reviving them. 

The judges noted that they may not be able to revive the stent patents, which cover various delivery methods for rapamycin to prevent arteries from narrowing after the stents are put in place, because they don't give enough information to allow another...
To view the full article, register now.